ZALTRAP™, CTNNB1 improve survival.

Two colorectal cancer studies released results on a new drug and a new biomarker. ZALTRAP™ shows promise as a second-line treatment of late stage disease. Examination of CTNNB1, a biomarker, revealed insights into a protein interaction that may explain increased survival in some obese colorectal cancer patients.

VELOUR trial evaluating the investigational agent ZALTRAP™ (aflibercept) in combination FOLFIRI [folinic acid (leucovorin), 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo showed improvement in overall survival (OS.) OS was the study’s primary endpoint, aimed at the second-line treatment of metastatic colorectal cancer (mCRC). ZALTRAP™ is also known as VEGF Trap. Read more…


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: